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Objective: This study was undertaken to determine the effect of nitric oxide (NO) on tissue factor (TF) expression in
vascular smooth muscle cells.
Study design: Rat aortic smooth muscle cells (RASMCs) were exposed to NO delivered exogenously with the NO donor
S-nitroso-N-acetylpenicillamine (SNAP) or produced endogenously after infection with an adenoviral vector carrying
human inducible NO synthase (AdiNOS). Functional TF activity was assessed with chromogenic TF assay. TF antigen
was determined with immunohistochemistry. Northern blot analysis was used to determine steady- state TF messenger
RNA (mRNA). Electrophoretic mobility gel shift assay was performed to determine the nuclear binding activity of
nuclear factor -B (NFB). NFB activity was inhibited by either prior transduction of RASMCs with mutant IB or
treatment with pyrrolidine dithiocarbamate.
Results: RASMCs exposed to SNAP or infected with AdiNOS exhibited increased functional TF activity and antigen.
Regardless of the source of NO, a time-dependent and concentration-dependent increase in TF activity was observed.
Steady-state TF mRNA levels were also increased by NO delivered via either method. NFB nuclear binding activity was
also increased by NO. Inhibition of NFB activity by either pyrrolidine dithiocarbamate treatment or mutant IB
transduction abrogated NO-induced enhancement of TF mRNA and functional activity.
Conclusion: In RASMC, NO exposure results in upregulation of TF functional activity, antigen, and mRNA. This effect
appears to be mediated by an NFB-dependent pathway. (J Vasc Surg 2003;37:650-9.)
Tissue factor (TF) is the primary initiator of clotting,
both normal and pathologic, in a large number of clinical
settings and animal models.1 Local upregulation of TF after
vessel injury can initiate localized clotting that prevents
hemorrhage. However, TF upregulation in injured vessels
and atherosclerotic plaque can lead to undesirable vascular
thrombosis, and widespread upregulation of TF may lead
to extensive microvascular thrombosis and organ failure, as
in sepsis.2 Because TF has important functions, its complex
regulation requires understanding. A central theme of TF
regulation is that it is enhanced under conditions of isch-
emia, injury, and inflammation but downregulated under
conditions of quiescence and homeostasis.3
Nitric oxide (NO) regulates many processes in the
vessel wall. NO produced by the constitutive endothelial
NO synthase (eNOS, NOS-3) regulates basal vascular tone
and limits platelet and leukocyte adhesion to the endothe-
lium.4,5 The inducible NO synthase (iNOS, NOS-2) is
upregulated in the vessel wall locally in atherosclerotic
plaque and at sites of vessel injury, and diffusely during
systemic inflammation such as sepsis or shock.4-10 In both
atherosclerotic plaque and at sites of vascular injury, vascu-
lar smooth muscle cells (VSMC), which are an important
cell type for expression of iNOS, may lose their normal
covering of endothelial cells. Endothelial cell coverage may
also be damaged in some instances of sepsis or shock. These
pathologic conditions are characterized by increased
thrombogenicity. Therefore it was hypothesized that NO
would regulate TF expression in VSMCs.
METHODS
Cell culture. This investigation conforms to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH Publ
No. 85-23, rev 1996). Rat aortic smooth muscle cells
(RASMCs) from male Sprague-Dawley rats (Harlan, Indi-
anapolis, Ind) were cultured from thoracic aortas as de-
scribed11 and were studied at confluence. Cultured cells
had the characteristic hills-and-valleys appearance and were
routinely more than 95% pure at -actin staining. Cells
were grown in Dulbecco’s modified Eagle’s medium (low
glucose)/Ham’s F12 (1:1) (BioWhittaker, Walkersville,
Md) supplemented with 10% fetal bovine serum, 100
U/mL of penicillin, 100 mg/mL of streptomycin, and 4
mmol/L of L-glutamine, and they were maintained in a
37° C, 95% air/5% carbon dioxide incubator. RASMCs
between passages 3 and 8 were used. For all experiments,
24 hours after plating RASMCs were placed in serum-free
media for 48 or 24 hours, respectively, to induce quies-
cence before treatment.
Because serum alone can increase TF expression,12
controls included both cells exposed to no serum and cells
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exposed to 10% serum only (labeled as 0% and 10%, respec-
tively, in the figures) after induction of quiescence. Except
where the absence of serum is specifically indicated by the
label 0%, all data displayed in the figures represent cells
treated with 10% serum in addition to any other stimulators
or inhibitors indicated by the labels. In some experiments,
nuclear factor -B (NFB) was inhibited by adding 100
mmol/L of pyrrolidine dithiocarbamate (PDTC; Sigma, St
Louis, Mo) 15 minutes before adding S-nitroso-N-
acetylpenicillamine (SNAP). In other inhibition studies we
used 10 mmol/L of the cyclic guanosine monophosphate
(c-GMP) inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxa-
lin-1-one (ODQ), 4 mmol/L of the transcription inhibitor
actinomycin D, or 40 mg/mL of the protein synthesis
inhibitor cycloheximide (all from Sigma).
Adenoviral vectors. Human inducible NO synthase
(iNOS) complementary DNA (cDNA) was cloned from
stimulated human hepatocytes.13 An E1-deleted and E3-
deleted adenoviral vector carrying human iNOS cDNA
(AdiNOS) was designed and constructed as previously de-
scribed.14 For the NFB inhibition experiments with mu-
tant IB, an E1-deleted and E3-deleted adenoviral vector
carrying the IB cDNA mutated at serines 32 and
36(AdIBSR) was designed and constructed as previously
described (generous gift of David Brenner, Chapel Hill,
NC).15 The serines at these positions were mutated to
alanines that cannot be phosphorylated.
Transduction of RASMCs in vitro. After 24 hours
of serum starvation, the cells were rinsed with Hanks’
balanced salt solution (Gibco, Grand Island, NY), then
infected for 4 hours at 37°C with a control adenoviral
construct or AdiNOS at 109 plaque-forming units (PFU)/
mL. This value was chosen based on previous experiments
that demonstrated a nontoxic level of nitrite production. At
this concentration, there is 20% to 30% transfection effi-
ciency.16 For mutant IB transduction experiments,
AdIBSR was used at a multiplicity of infection of approx-
imately 2  1010 PFU/mL. After another 24 hours of
starvation, the cells were treated with media containing
10% fetal bovine serum for the indicated time points.
Tetrahydrobiopterin (10 mmol/L) was added to the cul-
ture medium to optimize iNOS activity.17 One millimole
per liter of the NOS inhibitor L-N5-(1-iminoethyl)-orni-
thine dihydrochloride) (L-NIO; Alexis, Montreal, Canada)
was added to some treatment groups. To estimate NO
synthesis after adenoviral infection, nitrite accumulation
was assayed with the Griess reaction.18
Northern blot analysis. Total RNA was extracted
with TRIzol (Gibco BRL), electrophoresed on 1% formal-
dehyde-agarose gel, and transferred to a nylon membrane
(New England Nuclear, Boston, Mass). The membrane
was then hybridized with phosphorus 32-labeled cDNA
probes of human TF19 or rat TF (generous gifts from Karen
Fisher, Genentech) and 18S as control. Hybridized signals
were measured with scanning densitometry, and TF mRNA
levels were normalized to the 18S RNA levels.
TF functional assay. After exposure to the experi-
mental group, the medium was removed from each well of
the 24-well plate, and the cells were incubated with 150 mL
of 50 mmol/L Tris hydrochloride at pH 7.40, 50 mL of 2
U/mL factor VII (American Diagnostica, Greenwich,
Conn), and 50 mL of 2 U/mL factor X (American Diag-
nostica), and 25 mL of 50 mmol/L calcium chloride
(Sigma) for 2 hours. After stopping the reaction with 25
mL of 25 mmol/L ethylenediaminetetraacetic acid
(EDTA; Sigma), activated factor X (Xa) levels were mea-
sured with addition of a chromogenic substrate (Spec-
troyzyme FXa; American Diagnostica) to the supernatant.
After 2 minutes the absorption was measured in a spectro-
photometer at 405 nm. The measured absorption was
compared with a standard line generated with the chromo-
genic substrate and known amounts of factor Xa (American
Diagnostica). The positive control used in all assays was
150 mL of 11.6 mmol/L thromboplastin (Sigma).
Immunohistochemistry. Cells fixed with 10%buff-
ered formalin (Fisher Scientific, Atlanta, Ga) were incu-
bated with 2% hydrogen peroxide/60% methanol solution
for 30 minutes, then permeabilized with 0.1% Triton
X-100 for 20 minutes. The cells were blocked with purified
goat immunoglobulin G (1:20) for 30 minutes, incubated
with rabbit polyclonal anti-TF antibody (1:250; American
Diagnostica) for 1 hour, then with a secondary antibody for
1 hour (goat anti-rabbit immunoglobulin G, 1:200; Pierce,
Rockford, Ill). Cells were exposed to the ABC staining kit
reagents for 30 minutes (Pierce), then to diaminobenzidine
according to the manufacturer’s instructions (Pierce). The
cells were counterstained with aqueous hematoxylin
(Biomeda, Foster City, Calif) and mounted with gelvatol.
Light microscopy images were collected with a Provis mi-
croscope (Olympus, Tokyo, Japan).
Electrophoretic mobility shift assay. The electro-
phoretic mobility shift assay assay was used to detect acti-
vation and translocation of proteins that bind to specific
consensus DNA sequences of NFB. The cells were
washed, resuspended in phosphate-buffered saline solu-
tion, and centrifuged at 4500 rpm for 5 minutes in a
microfuge. The pelleted cells were resuspended in 0.5 mL
of buffer A (10 mmol/L of Tris [pH 7.5], 1.5 mmol/L of
magnesium chloride, 10 mmol/L of potassium chloride,
and 0.5% Nonidet P-40 [NP-40]) at approximately 5
packed cell volumes and disrupted with gentle pipetting.
Nuclei were recovered by microcentrifugation at 7000 rpm
for 5 minutes. The nuclear pellets were washed by resus-
pension in 500 mL of buffer B (buffer A without NP-40)
and pelleted by microcentrifugation at 7000 rpm. Nuclear
proteins were extracted at 4° C by gentle resuspension of
the nuclei in 50 mL of buffer C (20 mmol/L of Tris [pH
7.5], 10% glycerol, 1.5 mmol/L of magnesium chloride,
420 mmol/L of sodium chloride, 0.2 mmol/L of EDTA)
followed by 45 minutes of platform rotation. The nuclear
protein suspension was cleared by microcentrifugation at
13,000 rpm for 15 minutes. All buffers contained the
following additions: 1 to 2 mg/mL each of the protease
inhibitors aprotinin, benzamidine, chymostatin, leupeptin,
pepstatin, 0.2 mmol/L of phenylmethylsulfonyl fluoride,
10 mmol/L of zVAD (broad-spectrum caspase inhibitor),
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0.5 mmol/L of dithiothreitol, and 10 mmol/L of sodium
vanadate (phosphatase inhibitor). All steps were carried out
on melting ice or at 4° C. The nuclear proteins were
aliquoted and stored at 80° C. Protein concentrations
were measured with the BioRad protein assay, with bovine
serum albumin as a standard. NFB oligonucleotide DNA
probes derived from the immunoglobulin kappa light chain
enhancer sequence were prepared by end-labeling with
(-32P)adenosine triphosphate and T4 polynucleotide ki-
nase (Boehringer Mannheim, Indianapolis, Ind), purified
with ethanol precipitation and washing, followed by resus-
pension in 10 mmol/L of Tris-Cl, 1 mmol/L of EDTA
(pH 7.6) containing 100 mmol/L NaCl. Five micrograms
of nuclear proteins were incubated with 100,000 cpm of
32P-labeled consensus NF-B oligonucleotide (0.5 ng)
for 1 hour at room temperature. The nuclear proteins and
NF-B probe were incubated in a buffer containing 10
mmol/L of Tris-Cl (pH 7.5), 10% glycerol, and 0.2%
NP-40. The overall salt concentration of the 20 mL of
DNA-binding reaction was adjusted to 60 mmol/L of
sodium chloride. Poly (dI-dC)-poly (dI-dC) (Boehringer
Mannheim) was included in the DNA binding reactions at
0.5 mg as a nonspecific, competitor DNA. Protein-DNA
complexes were resolved on a standard 4% nondenaturing
polyacrylamide gel in 0.4  tris base/boric acid/EDTA
running buffer. After approximately 1 hour of electro-
phoresis at 180 V, gels were dried under heated vacuum
onto cellulose paper and subjected to autoradiography.
Statistical analysis. Results are expressed as mean 
SEM. Each condition, or group, in individual experiments
was performed in triplicate, and each of the reported exper-
iments was done at least twice, with different cultures.
When appropriate, the difference between two groups was
analyzed with the t test. Differences between more than
two groups were analyzed with one-way analysis of variance
with the Student-Newman-Keuls post hoc test for all pair-
wise comparisons (SigmaStat; SPSS, Chicago, Ill). Statisti-
cal significance was inferred at P 	 .05.
RESULTS
NO increases TF activity in RASMCs. To deter-
mine whether VSMC express TF and whether NO regu-
lates TF, RASMCs were exposed to the NO donor SNAP
in culture. RASMCs exposed to SNAP for 6 hours dem-
onstrated increased TF functional activity at concentra-
tions of 0.1 mmol/L and higher (Fig 1, A and B; *P 	
.05 vs controls). Time course analysis showed maximal
stimulated activity at 6 hours, with subsequent decline
(Fig 1, C; *P 	 .05; SNAP, 0.5 mmol/L).
The effect of endogenous NO production on TF ex-
pression by RASMCs was also studied. Cells infected with
AdiNOS produced high levels of nitrite compared with
other treatment groups (Fig 2, A; *P 	 .05) at 12 and 24
hours. These cells also demonstrated a significant increase
in TF activity compared with controls (Fig 2, B; *P 	 .05)
at the same time points. Inhibition of the effect by L-NIO
demonstrated that NO is the specific cause of the observed
TF enhancement (P 	 .05 vs AdiNOS).
Fig 1. Functional surface TF activity in RASMCs exposed to
SNAP. A, Nitrite production was measured with the Greiss reac-
tion. B, RASMCs exposed to SNAP (0.1 mmol/L and above) for
6 hours demonstrated significantly greater functional surface TF
activity compared with both controls. *P 	 .05. C, Increase in
functional surface TF activity with SNAP (0.5 mmol/L) was
transient, peaking at 6 hours. *P 	 .05. Groups performed in
triplicate. Error bars show SEM. Data represent six similar experi-
ments.
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NO increases TF antigen in RASMCs (Fig 3). To
confirm that not only activity but also TF protein increase,
TF antigen was measured. RASMCs maintained in media
with 10% serum expressed low basal levels of TF antigen.
Exposure to SNAP (0.5 mmol/L) for 6 hours resulted in an
increase in TF antigen expression (Fig 3, brown staining).
NO increases TF mRNA levels in RASMCs. To
begin to assess the level at which NO regulates TF expres-
sion, TF mRNA steady-state levels were measured in cells
exposed to NO. After 2-hour exposure to SNAP, RASMCs
exhibited a concentration-dependent increase in steady-
state mRNA levels of TF (Fig 4, A). This increase was not
due to the parent compound, because oxidized SNAP,
which no longer releases NO, did not evoke an increase in
TF mRNA levels (data not shown). Time course analysis is
shown in Fig 4, B. The greatest effect of SNAP on steady-
state mRNA levels for TF occurred at 1 and 2 hours, with
subsequent return toward baseline.
The next step was the study of the effect of endogenous
NO production on TF mRNA levels. Twenty-four hours
after infection of RASMCs with either AdiNOS or control
vector carrying the 
-galactosidase gene, AdlacZ, the cells
were collected for Northern blot analysis. Cells infected
with AdiNOS produced high levels of nitrite, a stable end
product of NO (Fig 4, C). There was a dramatic increase in
steady-state TF mRNA levels after AdiNOS infection (Fig
Fig 2. Functional surface TF activity in RASMCs infected with AdiNOS. A, In RASMCs infected with AdiNOS,
nitrite release was time-dependent. *P 	 .05 versus controls. B, Increase in functional surface TF activity was
time-dependent. *P 	 .05 versus all controls) after AdiNOS infection. NOS inhibitor, NIO, reversed increase in TF
activity (P 	 .05). Groups performed in triplicate. Error bars show SEM. Data represent four experiments.
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4, D; *P  .001). The increase was not due to the adeno-
viral vector alone, because cells infected with AdlacZ did
not show an increase in TF mRNA levels. The effect was
NO-specific, because treatment with L-NIO prevented the
increase (Fig 4, D; **P .002 vs. AdiNOS). In comparing
panels 4, A and 4, D, the differences in the magnitude of
serum-induced TF mRNA upregulation and quality of TF
mRNA signal may be due in part to the difference in
duration of exposure to the stimulators (2 vs 24 hours).
The effect of serum on TF mRNA is maximal at early time
points (1 to 2 hours) and dissipates rapidly at later time
points (data not shown).
Upregulation of TF by NO is not inhibited by 1H-
[1,2,4] oxidiazole [4,3-a] quinoxaline-1-one (ODQ) or
cycloheximide but is inhibited by actinomycin D (Fig 5).
Specific inhibitors were used to better characterize the
mechanism of NO-induced TF mRNA upregulation. Fig-
ure 5 shows that ODQ did not prevent TF mRNA upregu-
lation, suggesting that the mechanism is independent of
cGMP. Actinomycin D prevented TF mRNA upregulation,
suggesting that the effect of NO requires new transcription.
Cycloheximide caused marked upregulation of TF mRNA,
an effect similar to that observed with other highly regu-
lated gene products with levels controlled by continual
degradation. The effect of cycloheximide on TF mRNA
occurred whether or not SNAP was added (data not
shown).
NO exposure causes increased nuclear binding ac-
tivity of NFB. TF expression is NFB dependent in
several models.1 Therefore studies were performed to de-
termine whether NO upregulates NFB DNA binding in
RASMC cultures. Electrophoretic mobility gel shift assays
demonstrate that SNAP causes a significant increase in
NFB binding activity in RASMC nuclear extracts. As
shown in Figure 6, this effect can be abrogated by the
NFB inhibitor PDTC, and it does not occur with serum
stimulation alone. The effect is also abrogated by mutant
IB transduction (data not shown).
NFB inhibition prevents NO-induced upregulation of
TF mRNA (Fig 7) Additional studies showed that NFB
inhibition using either mutant IB transduction or PDTC
treatment prevented the NO-induced upregulation of TF
mRNA levels. SNAP (lane 6) upregulates the signal in
comparison to no stimulator (lane 9) or serum alone (lane
8). The effect of SNAP can be abrogated by PDTC (lanes 5
and 7) or transduction of RASMCs with mutant IB (lane
3). In contrast, transduction with LacZ (lane 1) does not
abrogate the effect of SNAP. The results of control trans-
duction with either mutant IB or LacZ (lanes 2 and 4) are
also shown.
DISCUSSION
TF is the principal initiator of coagulation. The TF-
factor VII complex initiates coagulation by activating fac-
tors IX and X.20 TF is not normally expressed by endothe-
lial cells or VSMC, but it is constitutively expressed by
adventitial fibroblasts and virtually all extravascular
cells.21,22 This localization preserves normal blood flow
intraluminally, but it initiates the coagulation cascade in the
event of vascular trauma. Upregulation of intravascular TF
occurs in many models of inflammation and stress, and its
upregulation is important in pathologic thrombotic events.
Fig 3. Staining for TF antigen in RASMCs exposed to SNAP. RASMCs were exposed to SNAP (0.5 mmol/L) for 6
hours, then stained for TF. Cells treated with SNAP but stained with PBS in place of primary antibody served as negative
control. Data represent three similar experiments.
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The reported data show that in cultured RASMCs NO
upregulates TF functional expression, TF antigen, and TF
mRNA. Furthermore, the data indicate that the mechanism
of TF upregulation is NFB-dependent.
NO is a short-lived free radical with diverse and impor-
tant vascular pathophysiologic effects. The effect of NO can
be beneficial and homeostatic under certain conditions but
deleterious and pathologic under other conditions.23 NO
has a major role both in maintaining the fluidity of blood
within the vascular system and in mediating extravascular
inflammation. Therefore one might predict some interplay
of TF and NO. Regulation of TF by NO has been previ-
ously reported in only a small number of studies.24-28
These studies have reached seemingly conflicting conclu-
sions. Gerlach et al26 found that NO reduces expression of
TF in lipopolysaccharide (LPS)-stimulated monocytes; in
contrast, Polack et al28 found that NO upregulates TF
expression by LPS-stimulated monocytes. Another study27
found that oral administration of L-arginine, a precursor of
NO, reduced TF expression in balloon-injured rat aorta.
However, Kobayashi et al24 found that inhalation of high-
dose NO activates the alveolar clotting system by increasing
lung expression of TF. Yang and Loscalzo25 found that
enhanced production of endothelium-derived NO reduces
endotoxin-induced and cytokine-induced expression of
TF. Based on these disparate results, it is clear that the effect
Fig 4. Northern blot analysis of steady-state TF mRNA levels in RASMCs. SNAP increase in steady-state TF mRNA
levels was (A) concentration-dependent (*P 	 .05 vs control) and (B) time-dependent (*P .002, **P  .03, #P 
.03 vs respective controls). C, RASMCs infected with AdiNOS produced substantially more nitrite compared with all
controls, as measured with the Greiss reaction. D, Steady-state TF mRNA levels were significantly greater in RASMCs
infected with AdiNOS versus all other groups (*P .001 vs all controls, **P  .002 vs AdiNOS). A-D, Graphs
represent data from three independent experiments. Error bars show SEM. A representative blot is shown above the
graph. Time of exposure to stimulus shown on the x-axis is 2 hours for A and 24 hours for D.
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of NO on TF expression varies dependent on cell type,
experimental model, duration of exposure to NO, and
dosage of NO. To our knowledge, TF regulation by NO in
VSMC has not been previously studied. Thus none of the
previous studies are directly comparable with the present
work. An intriguing aspect of our study is the possibility
that other known stimulators of TF (eg, cytokines such as
interleukin-1 and tumor necrosis factor) may exert their
effect through NO. Further study will be necessary to
address this possibility.
The conclusion than NO upregulates TF function is
strengthened by the close relationship between supernatant
nitrite assays and the observed elevation of TF activity (Figs
1 and 2). This correlation was observed with different doses
of SNAP and in time-course studies for both SNAP and
AdiNOS. NO-donor SNAP produced transient increases in
TF expression (Fig 1, C), but iNOS overexpression resulted
in more prolonged upregulation of TF activity (Fig 2, B).
This difference may be due to the SNAP half-life of 9 to 12
hours.29 In contrast to the short half-life of SNAP, infec-
tion with AdiNOS results in more prolonged production of
NO. The decline in TF upregulation after 6 hours, as well as
the later onset of TF upregulation in the case of AdiNOS,
are both consistent with the time course of nitrite levels. In
general, in vitro SNAP exposure at 50 to 100 mmol/L
corresponds to homeostatic in vivo concentrations of NO,
whereas SNAP exposure at 100 to 500 mmol/L corre-
sponds to sepsic concentrations of NO.10
The proposed interpretation of the data is also
strengthened by the use of different methods of NO deliv-
ery. Exogenous donors can release oxygen radicals other
Fig 6. Electrophoretic mobility gel shift assay shows increased
NFB binding activity in nuclear extracts after treating RASMCs
with SNAP for 1 hour. Graph represents densitometry analysis of
relevant lanes in the gel; lane with no stimulator (0%) was assigned
a value of 100. Graph shows mean of three experiments. Error bars
reflect SEM. Displayed autoradiograph is from one of the three
experiments.
Fig 5. Northern blot analysis of steady-state RASMC TF mRNA levels after 4-hour stimulation under various
conditions, demonstrating SNAP-induced TF mRNA upregulation and abrogation of this effect with actinomycin D.
ODQ did not prevent upregulation of TF mRNA. Cycloheximide resulted in a dramatic increase in steady-state TF
mRNA, similar to the effect observed with other gene products subject to tight regulation by constant degradation (bar
corresponding to cycloheximide is off the scale of the graph). Graph shows mean of three experiments. Error bars reflect
SEM. Displayed autoradiograph is from one of the three experiments.
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than NO, and therefore studies in which exogenous donors
are used alone must be interpreted with caution. The use of
an adenoviral vector to deliver the iNOS gene raises the
concern that response to the vector alone may contribute to
the observed responses. However, this was controlled for
by using the AdLacZ vector, which had no effect on TF
activity (Figs 2 and 4). In addition to demonstrating in-
creased TF function induced by SNAP, TF antigen was also
increased by SNAP (Fig 3).
Steady-state TF mRNA levels are increased by NO,
whether NO is delivered by SNAP or AdiNOS (Fig 4). One
interpretation of these data is that NO induces new tran-
scription of the TF gene. However, the alternative expla-
nation of reduced TF mRNA degradation is not excluded
by the data. The suppression of TF upregulation by actino-
mycin D (Fig 5) supports the hypothesis that new TF
mRNA transcription is induced by NO.
Because of the findings of increased TF activity, anti-
gen, and mRNA, the next step was investigation of the
subcellular pathways that may be involved. For several
reasons, it seemed appropriate to focus on the NFB path-
way. First, this pathway is important in mediating proin-
flammatory and prothrombotic states.23,30 Furthermore,
NFB translocation into the nucleus has been specifically
implicated as an initiator of TF mRNA transcription31-33
and as an important mediator of the effects of
NO.23,30,34,35 The reported data suggest that the enhance-
ment of TF by NO depends on NFB translocation into the
nucleus (Figs 6 and 7). This conclusion is strengthened by
the finding that two different methods of NFB inhibition
abrogated the effect of NO on TF mRNA.
One interpretation of these data is that in RASMCs NO
exposure results in NFB translocation into the nucleus,
leading to increased binding of NFB to the TF promoter,
causing increased TF mRNA transcription and translation.
However, these data do not entirely exclude other possibil-
ities, such as NO-induced changes in TF mRNA stability.
Nor do the data definitively show that NFB exerts its
effect by binding to the TF promoter. To test the proposed
model of TF regulation by NO, nuclear run-on studies and
studies with selectively deleted TF promoter constructs will
be performed in the future.
It is important to understand TF regulation by NO in
SMCs. Two specific areas in which such regulation may be
important are atherosclerotic plaque and acute vascular
injury. TF mRNA, protein, and functional activity are in-
creased in atherosclerotic plaque.36,37 Most of the in-
creased TF expression has been identified in the lipid core,
macrophages, and SMCs, but it is typically absent from
endothelial cells.36 TF procoagulant activity in coronary
atherectomy specimens was positively correlated with
thrombus.37 TF predominately located in cellular areas (eg,
macrophages, SMCs) was found in patients with unstable
angina, whereas TF located mostly in acellular areas was
found in patients with stable angina.38 Atherosclerotic
plaque expresses significantly higher levels of iNOS com-
pared with the normal artery.39-41 Overexpression of iNOS
may initiate apoptosis of the SMCs in atherosclerotic le-
sions, leading to acute plaque rupture,42 exposure of the
underlying TF-rich core, and thrombosis.43 Our data sug-
gest that, in addition to its possible role in apoptosis, iNOS
may be responsible for the increased presence of active TF
Fig 7. Northern blot analysis of steady-state RASMC mRNA levels after 2-hour stimulation under various conditions,
demonstrating NO-induced upregulation of TF mRNA and abrogation of this effect with either PDTC (at 25 or 100
mmol/L) or transduction with mutant IB (see text). Graph represents densitometry analysis of relevant lanes in gel;
lane with no stimulator (0%) was assigned a value of 100. Graph shows mean of three experiments. Error bars reflect
SEM. Displayed autoradiograph is from one of the three experiments.
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in plaque. Further investigation is needed to definitively
link iNOS expression to regulation of TF in this environ-
ment.
TF regulation by NO may also be important in acute
vascular injury. After arterial injury, iNOS expression in-
creases.44 Similarly, TF expression increases rapidly in arte-
rial SMCs in rat and rabbit models of arterial injury,45,46
and it has been implicated in the regulation of arterial
remodeling after injury.47 The thrombogenic significance
of injury-mediated TF induction remains to be determined,
because this TF is expressed in the media, which is pro-
tected from the circulation by the presence of an intact
internal elastic lamina and by the rapid deposition of plate-
lets on the luminal surface.48 The data raise the possibility
that an increase in NO production may account for the
increase in TF expression and that this in turn may repre-
sent a source of TF that is ready to initiate the coagulation
cascade at the site of injury in the event of exposure of the
underlying SMCs to circulating blood elements. NO has
important anti-platelet properties in acute vascular injury,
and possible regulation of a prothrombogenic pathway may
seem paradoxical. However, incompletely understood fac-
tors such as oxidative stress, NO source (eNOS vs iNOS),
and amount of NO may determine its role in the vascula-
ture.23
In summary, we present new data suggesting that
NO upregulates TF functional surface activity, antigen,
and mRNA in RASMC and that these effects depend on
NFB translocation into the nucleus. These data indicate
yet another important facet of the biology of NO, and
they add to the ever-growing list of regulators of TF
expression.
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